PMN
NASDAQProMIS Neurosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks44+40%
2026-03-012026-08-23
Mix1490d
- Other6(43%)
- SEC Filings4(29%)
- Earnings2(14%)
- Analyst1(7%)
- Insider1(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProMIS Neurosciences Inc.SCHEDULE 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
- SECProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form 10-Q filed by ProMIS Neurosciences Inc.10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProMIS Neurosciences Inc.SCHEDULE 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
- PRProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAnnounced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond
- INSIDERChief Development Officer Kaplan Johanne bought $30,324 worth of shares (2,280 units at $13.30), increasing direct ownership by 58% to 6,221 units (SEC Form 4)4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- PRProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026. The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET. Conference Call and Webcast Information: Date:August 13, 2026 Time:4:30 p.m. Eastern Time Dial-in:1-877-407-9
- SECProMIS Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
- PRProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease TrialNo ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of its lead drug candidate, PMN310, in patients with mild cognitive impairment due to Alzheimer’s disease or mild
- PRProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s DiseaseCambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in pati
- ANALYSTChardan Capital Markets initiated coverage on ProMIS Neurosciences with a new price targetChardan Capital Markets initiated coverage of ProMIS Neurosciences with a rating of Buy and set a new price target of $20.00
- PRProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC) Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfo
- SECSEC Form S-8 filed by ProMIS Neurosciences Inc.S-8 - ProMIS Neurosciences Inc. (0001374339) (Filer)
- PRProMIS Neurosciences to Participate in Upcoming Conferences in JuneCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings. Conference details below:Jefferies Global Healthcare Conference, June 2-4, 2026Location: New York, NYPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ETWebcast link: Click here.Virtual Alzheimer's R&D Day, organized by Wolfe Research, June 4, 2026Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.
- INSIDERSEC Form 4 filed by Director Wyman William W4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Eugene4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Warma Neil K4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Shafmaster Madge K.4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Cashman Neil4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Milbury Max A.4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Mandel-Brehm Josh4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Kaplan Johanne4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Alex Slanix Paul4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- SECProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
PMN FAQ
6 questionsWhat does ProMIS Neurosciences Inc. do?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA...Where does PMN stock trade?
ProMIS Neurosciences Inc. (PMN) is listed on NASDAQ.What sector and industry is PMN in?
ProMIS Neurosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PMN?
ProMIS Neurosciences Inc. has had 1 recent analyst action on file. The most recent action was from Chardan Capital Markets: Buy with a $2000.00 price target on 2026-07-27. Recent price targets cluster around $2000.00.What companies are similar to PMN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PMN side-by-side with any of them on Quantisnow.How can I track PMN on Quantisnow?
Quantisnow aggregates ProMIS Neurosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PMN to receive live email and push alerts on every new disclosure.